IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Evgen Pharma PLC - clinical stage drug development company - Notes that sulforaphane, the active ...

Alliance News 7 April, 2021 | 3:22PM
Email Form Facebook Twitter LinkedIn RSS

Evgen Pharma PLC - clinical stage drug development company - Notes that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by some variants of coronavirus. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.

"We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021," says Chief Executive Huw Jones.

Current stock price: 8.28 pence, up 1.0% on Wednesday

Year-to-date change: down 19%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Evgen Pharma PLC 0.80 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures